GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Open accessThe DOI matches its Crossref record; 213 of the 216 references it cites were found in a registry or an index.
Abstract
The intestine represents the body’s largest interface between internal organs and external environments except for its nutrient and fluid absorption functions. It has the ability to sense numerous endogenous and exogenous signals from both apical and basolateral surfaces and respond through endocrine and neuronal signaling to maintain metabolic homeostasis and energy expenditure. The intestine also harbours the largest population of microbes that interact with the host to maintain human health and diseases. Furthermore, the gut is known as the largest endocrine gland, secreting over 100 peptides and other molecules that act as signaling molecules to regulate human nutrition and physiology. Among these gut-derived hormones, glucagon-like peptide 1 (GLP-1) and -2 have received the most attention due to their critical role in intestinal function and food absorption as well as their application as key drug targets. In this review, we highlight the current state of the literature that has brought into light the importance of GLP-1 and GLP-2 in orchestrating intestine–microbiota–immune system crosstalk to maintain intestinal barrier integrity, inflammation, and metabolic homeostasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, GLP-1 mitigates liver inflammation and fibrosis by inhibiting the NF-κB pathway, reducing the release of pro-inflammatory cytokines such as TNF-α and IL-6, and thus suppressing inflammatory pathways.307,413”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [307]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Role of the gut microbiome in chronic diseases: a narrative review
Vijay, A., & Valdes, A. M. (2022) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00991-6 · Cited by 361
RetractedA human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 1×
“3 million gut microbial genes that constitute the microbiome [81,82].”
BackgroundJaneway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549
Increased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., Guiot, Y., Derrien, M., Muccioli, G. G., Delzenne, N. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219451110 · Cited by 4,511
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004) · Cell · doi:10.1016/j.cell.2004.07.002 · Cited by 4,251
Interactions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173
Interaction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947 · cited 3×
“The gut microbiota has been shown to function as an endocrine organ, producing and regulating numerous compounds that reach the circulation and act to influence the function of distal organs and systems, actively taking part in amino acid generation, pathogen displacement [148], as well as circadian rhythmicity, nutri…”
BackgroundInfluential
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“307,413 In terms of apoptosis inhibition, GLP-1 activates the PI3K/Akt signaling pathway, enhances the expression of the anti-apoptotic protein Bcl-2, and inhibits the activation of caspase family proteins, reducing cell apoptosis.”
BackgroundSahoo, D. K., Heilmann, R. M., Paital, B., Patel, A., Yadav, V. K., Wong, D., & Jergens, A. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1217165 · Cited by 339
Pillai, S. S., Gagnon, C. A., Foster, C., & Ashraf, A. P. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae499 · Cited by 200
The intestine as an endocrine organ and the role of gut hormones in metabolic regulation
Bany Bakar, R., Reimann, F., & Gribble, F. M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00830-y · Cited by 144
“Like other gut hormones, such as serotonin and neurotensin, GLP1 and GLP2 also affect barrier function and modulate the immune system 59,60 .”
BackgroundA Comprehensive Review of the Triangular Relationship among Diet–Gut Microbiota–Inflammation
Randeni, N., Bordiga, M., & Xu, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179366 · Cited by 127
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“The underlying mechanisms are yet to be elucidated in detail but modi fi cations of gastric emptying, along with changes in caloric intake, and modi fi cations in gut pH levels and nutrient availability are being evaluated [174].”
BackgroundPaul, J. K., Azmal, M., Haque, A. S. N. B., Meem, M., Talukder, O. F., & Ghosh, A. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i5.99913 · Cited by 87
Khan, M. T., Zohair, M., Khan, A., Kashif, A. W., Mumtaz, S., & Muskan, F. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112599 · Cited by 77
Zikou, E., Dovrolis, N., Dimosthenopoulos, C., Gazouli, M., & Makrilakis, K. (2023) · Nutrients · doi:10.3390/nu15214663 · Cited by 71
“This was crucial because certain anti-diabetic medications, such as metformin [74] and GLP-1 RAs [75], have been shown to interact with and partially exert their actions through the intestinal microbiome.”
BackgroundHamamah, S., Hajnal, A. S., & Covașă, M. (2024) · Nutrients · doi:10.3390/nu16071071 · Cited by 72
“GLP-1 and GLP-2 are gut hormones that are enzymatically cleaved from proglucagon and are secreted by intestinal L-cells [182].”
BackgroundMetaflammation’s Role in Systemic Dysfunction in Obesity: A Comprehensive Review
Crasan, I.-M., Tanase, M., Delia, C., Pîrcălăbioru, G. G., Cîmpean, A., & Ionica, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110445 · Cited by 46
Stanimirov, B., Đanić, M., Pavlović, N., Zaklan, D., Lazarević, S., Mikov, M., & Stankov, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262412167 · Cited by 43
“Enteroendocrine L cells, which secrete glucagon-like peptide-1 (GLP-1), express a wide array of receptors responsive to metabolites derived from the intestinal microbiota, including GABA, SCFAs, and 5-HT [149].”
Molecular mechanisms of gut microbiota in diabetic nephropathy
Cheng, G., Liu, Y., Guo, R., Wang, H., Zhang, W., & Wang, Y. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111726 · Cited by 33
The Role of Gut Microbiota in the Onset and Progression of Obesity and Associated Comorbidities
Enache, R. M., Profir, M., Roşu, O. A., Creţoiu, S. M., & Gașpar, B. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212321 · Cited by 37
da Silva, R. S., de Paiva, I. H. R., Mendonça, I. P., de Souza, J. R. B., Lucena‐Silva, N., & Peixoto, C. A. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01603-y · Cited by 39
“Another factor to be considered is the suppression of gut inflammation since GLP-1R is present in immune cells (Abdalqadir and Adeli 2022; Alharbi 2024).”
GLP‐1 agonists and the gut microbiome: A bidirectional relationship
Kamath, S., Chan, N. S. L., & Joyce, P. M. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70487 · Cited by 44
“17,24,63,64 It orchestrates a finely tuned interplay between pancreatic α , β and δ cells, stimulating insulin secretion, suppressing glucagon release and modulating δ -cell-derived somatostatin, thereby regulating gastric motility and nutrient absorption.”
Al-Marzooqi, S. K., Almarzooqi, F., Sadida, H. Q., Jerobin, J., Ahmed, I., Abou‐Samra, A., Fakhro, K. A., Dhawan, P., Bhat, A. A., & Akil, A. A. (2024) · Obesity Reviews · doi:10.1111/obr.13766 · Cited by 36
Wu, X., Zhao, L., Zhāng, Y., Li, K., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1166685 · Cited by 31
“GLP-2 improves gut barrier function, enhances intestinal blood flow, ameliorates inflammation, and repairs damaged intestinal epithelium (Abdalqadir and Adeli, 2022; Yan et al., 2016).”
BackgroundThe promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 43
“At the gut barrier, GLP-1RAs improve epithelial integrity, reduce tight junction permeability, and suppress endotoxin translocation, thereby lowering systemic LPS-driven inflammation (105).”
Liu, J., Qiao, B., Cai, Y., Tan, Z., & Deng, N. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02896-9 · Cited by 29
Hypoglycemic effect of C. butyricum -pMTL007-GLP-1 engineered probiotics on type 2 diabetes mellitus
Zhou, D., Li, S., Hu, G., Wang, Y., Qi, Z., Xu, X., Wei, J., Liu, Q., & Chen, T. (2025) · Gut Microbes · doi:10.1080/19490976.2024.2447814 · Cited by 30
“54 Therefore, we analyzed the gut microbial alterations in each group by 16S rRNA high-throughput sequencing.”
Clarke, L. M., Pasam, R. T., Falahee, B. E., Jirapinyo, P., Allegretti, J. R., & Kelly, C. R. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08964-6 · Cited by 27
Zhan, M., Yang, X., Zhao, C., Han, Y., Xie, P., Mo, Z., Xiao, J., Cao, Y., Xiao, H., & Song, M. (2024) · Food & Function · doi:10.1039/d3fo04378a · Cited by 26
Shen, Z., Hou, Y., Zhao, G., Tan, L., Chen, J., Dong, Z., Ni, C., & Pei, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25459 · Cited by 38
“This peptide promotes intestinal mucosal growth, inhibits gastric acid secretion, weakens the peristalsis of the intestine, and enhances GLUT-2 expression [53 – 55].”
BackgroundThe role of gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy
Xie, L., & Lin, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1604315 · Cited by 28
Kanbay, M., Al-Shiab, R., Shah, E., Özbek, L., Güldan, M., Ortíz, A., & Fouque, D. P. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf351 · Cited by 28
“This is partly due to modulation of inflammatory signaling pathways and improvement of mucosal function, for example, by modulating the metabolism of bile acids [18 ,19 ], and by increasing beneficial microbes that support gut homeostasis [4 ].”
Gut Microbiota and Immunotherapy for Alzheimer’s Disease
Dai, C., Liu, F., Iqbal, K., & Gong, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315230 · Cited by 25
“Dynamic interactions between the gut microbiota and the host’s innate and adaptive immune systems play an important role in the modulation of host immunity homeostasis [19].”
BackgroundZhan, M., Liang, X., Chen, J., Yang, X., Han, Y., Zhao, C., Xiao, J., Cao, Y., Xiao, H., & Song, M. (2023) · Food & Function · doi:10.1039/d3fo00516j · Cited by 21
González-Luis, A., Llinares-Arvelo, V., Martínez‐Alberto, C. E., Hernández-Carballo, C., Fernández, C. M., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf223 · Cited by 23
Wang, J., Chang, S.-Y., Jin, Z.-Y., Li, D., Zhu, J., Luo, Z., Han, S., Kang, J., & Quan, L. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c03818 · Cited by 19
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
“Both preclinical and clinical studies have demonstrated that GLP-1 ’ s modulate the gut microbiota composition by delaying gastric emptying and altering luminal glucose (12).”
The Gut-Brain Axis in Alzheimer’s and Parkinson’s Diseases: The Catalytic Role of Mitochondria
Candeias, E., Pereira-Santos, A. R., Empadinhas, N., Cardoso, S. M., & Esteves, A. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240524 · Cited by 16
Oral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
Targeting Sarcopenia in CKD: The Emerging Role of GLP-1 Receptor Agonists
Llinares-Arvelo, V., Martínez‐Alberto, C. E., González-Luis, A., Macía-Heras, M., Siverio-Morales, O., Navarro‐González, J. F., & Donate‐Correa, J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26168096 · Cited by 15
Ganamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01834-y · Cited by 16
“Microbial metabolites including short chain fatty acids and bile acid derivatives modulate enteroendocrine L cell activity through GPR41/43, TGR5 and FXR signalling pathways, thereby regulating endogenous GLP 1 secretion and receptor tone [ 41, 49].”
Micic, Polovina, S. P., Micic, D., & Μacut, D. (2023) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2023.234 · Cited by 17
Musso, G., Pinach, S., Saba, F., Michieli, F. D., Cassader, M., & Gambino, R. (2024) · Med · doi:10.1016/j.medj.2024.03.014 · Cited by 13
Gomes, S. F., Valois, A., Estevinho, M. M., Santiago, M., & Magro, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312852 · Cited by 11
“…cytokine processing, immune cell activation, and chemokine-mediated migration, thereby shaping inflammatory responses and immune homeostasis [17–21, 35, 36, The findings from DPP4-related and gut microbiome assessments compiled in this rapid review highlight the bidirectional relationship…”
InfluentialPrisco, S. Z., Blake, M., Kazmirczak, F., Moon, R. A., Kremer, B. P., Hartweck, L. M., Kim, M., Vogel, N. T., Mendelson, J. B., Moutsoglou, D., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012524 · Cited by 15
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
“The Potential Role of GLP‑2 GLP-2 is a peptide hormone composed of 33 amino acids, derived from the cleavage of proglucagon and secreted by enteroendocrine L cells in the small intestine [126].”
Tao, W., Yu, Y., Tan, D., Huang, X., Huang, J., Lin, C., & Yu, R. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1603442 · Cited by 9
Understanding the role of the human gut microbiome in overweight and obesity
McBurney, M. I., & Cho, C. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15215 · Cited by 21
Sellami, E., Evangelista-Silva, P. H., Teixeira, C. J., Diop, K., Mitchell, P., & Anhê, F. F. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102101 · Cited by 9
“Firstly, unlike Glp2, Glp1 exhibits limited gut trophic effects [47] and has been shown to have minimal involvement in the acute response to nutrient sensing when derived from the distal gut [48].”
Pelc, A., Fic, W., Typrowicz, T., & Polak-Szczybyło, E. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080637 · Cited by 12
“Suppressing hunger at the CNS level, slowing down of gastrointestinal motility, and via side effects (bloating, diarrhea, nausea, inflammation and pancreatic cancer) [147,148].”
Baccari, M. C., Vannucchi, M. G., & Idrizaj, E. (2024) · Nutrients · doi:10.3390/nu16183069 · Cited by 11
“[41] from which it is co-secreted in a 1:1 ratio [42] and the molecular mechanisms that link hormone exocytosis to the circulating patterns of glucagon-like peptides are only recently beginning to be fully understood [27].”
BackgroundGut Microbiota and Diabetes: Pioneering New Treatment Frontiers
Shakya, R., Sivakumar, P. M., & Prabhakar, P. K. (2025) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303342579241119155225 · Cited by 13
Mechanisms of Insulin Signaling as a Potential Therapeutic Method in Intestinal Diseases
Jarmakiewicz-Czaja, S., Sokal-Dembowska, A., Ferenc, K., & Filip, R. (2024) · Cells · doi:10.3390/cells13221879 · Cited by 8
Composition, function, and detection methods of the intestinal barrier
Sun, N., Liu, W., Li, J., Zhang, D., Liu, X., Liu, J., & Hu, H. (2025) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2025.110179 · Cited by 11
The Leaky Gut and Human Diseases: “Can’t Fill the Cup if You Don’t Plug the Holes First”
Compare, D., Sgamato, C., Rocco, A., Coccoli, P., Ambrosio, C., & Nardone, G. (2024) · Digestive Diseases · doi:10.1159/000540379 · Cited by 10
“GLP-2, a cleavage product of glucagon released by intestinal enteroendocrine cells, plays a crucial role in maintaining the growth and absorptive function of the intestinal epithelium [99].”
The Potential Mechanism of Remission in Type 2 Diabetes Mellitus After Vertical Sleeve Gastrectomy
Wang, R., Mijiti, S., Xu, Q., Liu, Y., Deng, C., Huang, J., Yasheng, A., Tian, Y., Cao, Y., & Su, Y. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07378-z · Cited by 9
“At present, GLP-2 and its analog are considered primarily as a novel therapy for short bowel syndrome [83–85].”
Lipid regulation of the glucagon receptor family
Oqua, A. I., Manchanda, Y., McGlone, E. R., Jones, B. J., Rouse, S. L., & Tomás, A. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0335 · Cited by 8
GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Jiang, H., & Zang, L. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128283153231226103218 · Cited by 7
Indole-3-carboxyaldehyde does not reverse the intestinal effects of fiber-free diet in mice
Smits, M. M., Dreyer, S. I. L., Hunt, J. E., Drzazga, A. K., Modvig, I. M., Holst, J. J., & Kissow, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1362711 · Cited by 6
Research Progress on the Relationship Between the Intestinal Barrier and Macrophages
Ma, S., Zhu, K., Liu, Y., & Wang, J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47100813 · Cited by 6
“…2 (GLP-2) augments intestinal barrier integrity through dual mechanisms: expanding stem cell populations to drive epithelial proliferation while suppressing NLRP3 inflammasome activation, thereby bolstering tight junctions and curtailing LPS translocation into the circulation [5] (Figure 1).”
Potrykus, M., Stanisławowski, M., Czaja-Stolc, S., Potrykus, A., Stankiewicz, M., Owczarzak, A., Guzek, M., Szymański, M., Łoniewski, I., Adrych, K., et al. (2025) · Nutrition Journal · doi:10.1186/s12937-025-01217-2 · Cited by 6
“Ghrelin and leptin control appetite and energy balance [27], while SCFAs produced by gut microbiota activate GPR41 and GPR43 receptors on enteroendocrine cells (EECs), influencing GLP-1 secretion, which regulates glucose metabolism and suppresses appetite [28, 29].”
Intestinal interoception: A nexus of environment-body-brain interactions
Salvador, A. F. M., Golynker, I., Betley, J. N., & Thaiss, C. A. (2026) · Neuron · doi:10.1016/j.neuron.2025.11.026 · Cited by 6
Gut microbiota and stress ulcers: unraveling the neurotransmitter connection
Abdel-Sater, K. A., & Hassan, H. A. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1594179 · Cited by 11
Choi, Y. R., & Kim, M. J. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105198 · Cited by 4
Ligands for Intestinal Intraepithelial T Lymphocytes in Health and Disease
Hada, A., & Xiao, Z. (2025) · Pathogens · doi:10.3390/pathogens14020109 · Cited by 5
“Additionally, T-IELs also express GLP2R, the receptor for glucagon-like peptide 2 (GLP2), which regulates intestinal barrier function and suggests a role in epithelial maintenance [75,103,104].”
Irfan, Z., Halder, J., Giri, S., Molla, E. A., & Khanam, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113102 · Cited by 6
Huang, W., Liu, J., Zhao, Y., Zhang, H., Han, W., Zheng, K., Li, J., & He, X. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116690 · Cited by 6
Gómez‐Bruton, A., Irún, P., Matute-Llorente, Á., Lozano‐Berges, G., Moradell, A., Ara-Gimeno, S., Subías-Perié, J., Sánchez‐Luengo, M., Hijos, G., García, S. G., et al. (2024) · Trials · doi:10.1186/s13063-024-08221-7 · Cited by 5
“The intervention exerts a profound influence on appetite and glucose homeostasis, with gut-derived hormones and the intricate interplay between microbiota, intestine, liver, immune system, and brain playing a pivotal role [10, 11].”
BackgroundÇalık, A., Niraula, A., Dong, B., Blue, C. E. C., Fenster, D. A., & Dalloul, R. A. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1520346 · Cited by 4
Evolution and therapeutic potential of glucagon-like peptide 2 analogs
Binbin, G., Wang, T., & Sun, L. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116758 · Cited by 4
Zhang, W., den Bossche, W. V., Yagoubi, H., Kambale, E. K., Wahni, K., Saxena, T., Guilbaud, L., Moreels, T. G., Messens, J., & Beloqui, A. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202403497 · Cited by 3
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“These agents also increase cyclic adenosine monophosphate (cAMP) levels and modulate pro-inflammatory genes in intraepithelial lymphocytes [141], contributing to decreased intestinal inflammation in animals [145,146].”
Systemic evaluation of the effects of monomeric GLP-1R-based agonists on MASLD and its complications
Cai, Y., Xie, S., Xu, L., Chen, J., & Cai, J. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01870-x · Cited by 3
“Furthermore, GLP-1R activation can mitigate liver inflammation and fibrosis by suppressing the NF-κB signaling pathway and downregulating pro-inflammatory cytokines like tumor necrosis factor α (TNF-α) and Interleukin-6 (IL-6) [47, 48].”
Cai, Y., Xie, S., Xu, L., Chen, J., & Cai, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178088 · Cited by 2
Host–Microbiota Interactions in Obesity: Immune Metabolic Dysregulation
Zhihan, N., Weiyu, G., Luo, G., & Hong, Y. (2026) · Obesity Reviews · doi:10.1111/obr.70110 · Cited by 3
Khan, J., Gul, P., Chang, M., Li, Q., & Liu, K. (2026) · Food Research International · doi:10.1016/j.foodres.2026.118675 · Cited by 2
Unraveling the mechanisms of PCOS: the interplay between gut microbiota and the immune system
Liu, J., Wang, L., Jiang, M., Yan, H., Zhang, G., Li, N., Zhao, Y., Du, X., Zeng, Q., Xiong, D., et al. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02047-4 · Cited by 4
“Microbes and their metabolites can enter host cells through the intestinal mucosal epithelial layer, subsequently influencing the immune system, either maintaining a normal immune state or promoting the development of diseases [67–70].”
Tang, X., Hu, A., Xu, Q., Yu, J., Zheng, S., Hu, Y., Zhu, Y., Ye, M., Lv, T., & Liu, Z. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103136 · Cited by 2
The Secret Life of Microbes: The Expanding Role of Microbes in Shaping Endocrine Health
Al-Salami, I., AL-Daami, Q. J., Bash, H. S., Mahdy, A. S., & Al-Hindy, H. A.-A. M. (2024) · GenoMed Connect · doi:10.69709/genomc.2024.193113 · Cited by 2
Łoniewski, I., Banasiewicz, T., Sieńko, J., Skonieczna‐Żydecka, K., & Stachowska, E. (2024) · Gastroenterology Review · doi:10.5114/pg.2024.145833 · Cited by 6
“Glucagon-like peptide 1 and peptide YY can reduce fat deposition in liver cells by modulating L-cells [112, 113].”
Voudren, C. D., Mayhue, E. J., Riehm, M. D., & Jugan, M. C. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305711 · Cited by 2
Heinecke, F., Fornes, D. D., Capobianco, E., Quiroga, J. P. F., Labiano, M., Faletti, A. G., Jawerbaum, A., & White, V. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112201 · Cited by 2
Jaramishian, C., Kamal, S., Martı́n, M. G., & Minkoff, N. Z. (2024) · JPGN Reports · doi:10.1002/jpr3.12125 · Cited by 1
Biouss, G., Lee, C., Li, B., Adeli, K., & Pierro, A. (2025) · Pediatric Surgery International · doi:10.1007/s00383-024-05957-w · Cited by 2
Self-citationZhang, X., Li, C., Deng, Z., Liang, C., & Li, J. (2025) · Molecules · doi:10.3390/molecules30091915 · Cited by 1
“As a naturally occurring gut hormone, GLP-2 not only promotes nutrient absorption by decreasing intestinal motility and permeability, but also plays a pivotal role in stimulating intestinal epithelial cell growth and function [34].”
GLP-1 (Glucagon-Like Peptide-1)
Ross, S. M. (2025) · Holistic Nursing Practice · doi:10.1097/hnp.0000000000000753 · Cited by 1
Weaning Influences Epithelial Morphology, Gene Expression and Gut Microbiota Composition in Piglets
Mouchtoglou, C., Goossens, E., Aluwé, M., Ducatelle, R., & Immerseel, F. V. (2026) · Animals · doi:10.3390/ani16060961 · Cited by 2
Gunnar, R., Mutanen, A., Pakarinen, M. P., & Merras‐Salmio, L. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70437 · Cited by 1
“6 Together, these mechanisms are considered to mediate the reduction of PS dependence in SBS.”
Jeppesen, P. B. (2026) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0000000000001296 · Cited by 1
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“SCFAs activate GPR41/43 on L cells, enhancing endogenous GLP-1 secretion [91], while strengthening epithelial junctions and reducing inflam - mation [92, 93].”
Bacteria, Viruses, and the Microbiome
Anisman, H., Hayley, S. P., & Kusnecov, A. W. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.00020-x
Raoul, P. C., Cintoni, M., Rinninella, E., & Mele, M. C. (2023) · Microorganisms · doi:10.3390/microorganisms11040985
“These peptides can preserve metabolic homeostasis and gut barrier integrity [17].”
BackgroundMicrobiome and Circadian Rhythms: Implications for Sleep, Aging, and Therapeutic Strategies
Najumuddin, Ullah, I., Taqveem, A., & Khurshid, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-3790-1_10
Non-surgical Interventions for Improving Nutrient Absorption in Pediatric Short Bowel Syndrome
Faintuch, J., Lee, A. D. W., Faintuch, S., Mishaly, A., & Karkow, F. J. (2024) · Nutrition and Dietary Supplements · doi:10.2147/nds.s405620
(2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23565-8.09996-8
Nagano, A., Tsuruno, Y., Sugita, K., Onishi, S., Tabata, Y., Kedoin, C., Murakami, M., Yano, K., Harumatsu, T., Kawano, T., et al. (2025) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2025.162472
Иванова, Е. М., Косьмина, К. О., Шумков, А. Ю., Забежинский, А. М., Майорова, А. М., & Раевский, К. П. (2025) · Успехи геронтологии · doi:10.34922/ae.2025.38.2.010 · Cited by 4
Ugwu, O. P.-C., Ugwu, M. N., Basajja, M., & Anyanwu, C. N. (2025) · Obesity Medicine · doi:10.1016/j.obmed.2025.100639 · Cited by 1
Dietary Modulation of the Gut Microbiome: A Promising Approach for Management of Diabetes
Chukwudozie, K. I., Chukwudozie, I. C., & Onyeka, C. P. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i10.7423
Tang, Q., Liang, Y., Liu, P., Tong, B., Shan, S., Chen, H., & Shang, S. (2025) · Interdisciplinary Nursing Research · doi:10.1097/nr9.0000000000000109
Capitalizing on the GLP-1 RA revolution for behavioral health through digital companions
Naegele, C., & Jones, G. B. (2025) · Digital Health · doi:10.1177/20552076251406308
Mahdavi, A., Greffard, K., Trottier, J., Barbier, O., Bilodeau, J., Lebel, M., & Rudkowska, I. (2025) · Lifestyle Genomics · doi:10.1159/000550224
Joshi, R., Dwivedi, J., Singh, S., Paliwal, S., Sharma, S., Mishra, A., & Singh, S. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02357-0
Jiang, Y., Han, G., Zhang, Z., Hu, S., & Mu, M. (2026) · Comprehensive physiology · doi:10.1002/cph4.70144 · Cited by 1
Fecal DPP4 concentration reflects colonic injury in the TNBS-induced rat model of colitis
Gomes, S. F., Ferreira‐Duarte, M., Dias‐Pereira, P., Couto, J., Duarte‐Araújo, M., Morato, M., & Magro, F. (2026) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00030.2026
Metadata
- Authors
- Abdalqadir, N., & Adeli, K.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Adeli, Khosrow
- ORCID
- Adeli, Khosrow
- Venue
- Microorganisms
- Publisher
- MDPI AG
- Published
- 2022-10-19
- Volume
- 10
- Issue
- 10
- Pages
- 2061
- ISSN
- 2076-2607 (ISSN-L)
- PMC
- PMC9610230
- OpenAlex
- W4306848286
- Cited by
- 119
- References
- 216
- Citations by year
- 2026: 36 · 2025: 38 · 2024: 36 · 2023: 8 · 2022: 1
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Microorganisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Canadian Institute of Health Research (CIHR) (FDN-148396)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- glucagon-like peptide-1, glucagon-like peptide-2, intestinal barrier integrity, gut microbiota, intestinal immunity, gut-brain-microbiota axis, intestinal inflammation, metabolic homeostasis, gastrointestinal hormones, intestinal endocrine cells, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.